The classification of brain tumors has traditionally depended on microscopic examination of hematoxylin and eosin-stained tissue sections. The increased understanding of clinically relevant genetic alterations has led to the incorporation of molecular signatures as part of the diagnosis of brain malignancies. Advances in sequencing technologies have facilitated the use of next-generation sequencing (NGS) assays in clinical laboratories. We performed a retrospective analysis of sequencing results for 381 brain tumors tested by NGS at our institution using a validated, commercially available panel. The results of the NGS assay were analyzed in conjunction with the results of immunohistochemical stains. A genetic alteration was detected in approximately two thirds of the cases. The most commonly mutated genes were TP53 (37.2%), IDH1 (29.4%), PIK3CA (8%), PTEN (8%), and EGFR (7.5%). BRAF mutations were detected in 3% of the cases, including 50% of gangliogliomas and 20% of gliosarcomas. No mutations were detected in 6 medulloblastomas. PIK3CA and CTNNB1 mutations were detected in 1 rosette-forming glioneuronal tumor and 1 adamantinomatous craniopharyngioma, respectively. Approximately 23% of cases showed amplification of 1 or more of the genes included in the NGS panel. This analysis demonstrates the utility of NGS for detecting genetic alterations in brain tumors in the clinical setting.
INTRODUCTION
The management of patients with brain tumors has largely been dependent on a classification system that until recently was based almost exclusively on microscopic examination of hematoxylin and eosin (H&E)-stained tissue sections and immunohistochemical evaluation of protein expression. The increased understanding of clinically relevant genetic alterations in brain tumors has led to the incorporation of molecular signatures in the diagnostic evaluation of brain malignancies (1) . With the publication of the revised 2016 WHO classification of tumors of the central nervous system (CNS), molecular testing of brain tumors becomes an important part of the diagnostic workup of CNS neoplasms (1) (2) (3) . Within the group of infiltrating gliomas, clinically relevant entities are now defined by molecular alterations with the goal of creating diagnostic categories that are more reproducible and have greater prognostic value (4) . The modifications to the diagnostic criteria incorporated in the WHO 2016 classification highlight the increasingly important role of molecular diagnostics for the future of oncologic neuropathology (3, 5) .
The advances in sequencing technologies over the past years have led to the incorporation of next-generation sequencing (NGS) assays in many clinical laboratories (6) (7) (8) .
Research interests and the highly publicized efforts towards personalized cancer treatment have created a demand for molecular profiling of tumors, including brain neoplasms (7, 8) . Large-scale efforts for genomic characterization of brain tumors have taken place in recent years and have generated a large amount of information that has revolutionized the practice of neuropathology (9) (10) (11) (12) (13) . Some examples of genetic alterations with clinical utility include combined IDH mutations and 1p/19q co-deletion as the molecular definition of oligodendrogliomas and the diagnostic and prognostic value of IDH mutations for infiltrating astrocytomas (14) (15) (16) .
We performed a retrospective analysis of the sequencing results for 381 brain tumors tested at our institution using a validated, commercially available NGS panel (17) . The goal of the study was to gain understanding of the most common genetic alterations detected by a commercial NGS assay in a large cohort of primary brain tumors. We also explored how the results of the NGS assay relate to immunohistochemical tests that have been a routine part of the diagnostic evaluation of brain tumors for many years. Ultimately, we evaluated the clinically useful information obtained with the NGS panel and discuss our results in the context of the revised WHO 2016 classification of CNS tumors.
MATERIALS AND METHODS

Cases
Electronic medical records at The University of Texas MD Anderson Cancer Center were retrospectively searched to identify brain tumors that were tested for genetic alterations by an NGS panel. A retrospective analysis of NGS, fluorescence in situ hybridization (FISH), and immunohistochemistry (IHC) results of 381 primary brain tumors was performed.
Immunohistochemistry
IHC for detection of IDH1-R132H (clone H09, 1:40; Histobiotech), P53 (clone D07, 1:100; Dako, Carpinteria, CA), EGFR (clone 31G7, 1:50; Invitrogen, Billerica, MA), and PTEN (clone 6H2.1, 1:100; Dako) was performed using formalin-fixed, paraffin-embedded tumor tissue sections on an automated Bond Max (Leica Microsystems, Buffalo Grove, IL). IHC interpretation was performed by a board certified neuropathologist in all cases.
DNA Extraction
DNA was extracted from formalin-fixed, paraffinembedded tumor samples. Unstained 4-mm-thick tissue sections were deparaffinized, and tumor tissue was manually micro-dissected using as a guide an H&E-stained slide from the same block. H&E-stained tissue sections were reviewed by pathologists who circled the tumors and indicated the tumor percentage. Only specimens with >20% tumor in the circled area were included in the study. DNA was extracted using PicoPure DNA extraction kit (Arcturus, Mountain View, CA) and was purified using an Agencourt AMPure XP kit (Agencourt Biosciences, Beverly, MA). A Qubit DNA high-sensitivity assay kit (Life Technologies, Grand Island, NY) was used to quantify purified DNA. ABL1, AKT1, ALK, APC,  ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR,  ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3,  FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2,  JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1,  NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1,  RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53 , and VHL. At least 10 ng of DNA extracted from formalin-fixed, paraffin-embedded tumor was used as a template. Sequencing was performed using the sequencing kit (Life Technologies) as per the manufacturer's instructions. A cutoff point of 300,000 reads with a quality score of AQ20 (1 misaligned base per 100 bases) was used as a measure of successful sequencing of a sample. This corresponds to an average sequencing coverage depth per amplicon of approximately 1,500. For a sequence variant to be considered authentic, sequencing coverage of 250 for negative calls and a variant frequency of at least 5% in the background of wild type were used as minimum requirements.
Next-Generation Sequencing
Estimation of Gene Amplification From NGS Depth of Coverage Data
Average coverage depths per amplicon and per sample were calculated using the TorrentSuite coverageAnalysis plugin, and normalized to derive a genic normalized coverage ratio for each sample and gene, as previously described (18) . A high cutoff of 3 previously shown to have very high positive predictive value for FISH and microarray validated amplification was employed: this corresponds to an estimated copy number of 8 ( 2 3 ) if assuming no germline DNA contamination.
Fluorescence In Situ Hybridization
The in situ hybridization technique was performed using an LSI 1p36 (TP73/MEGF6) SO/LSI 1q25 (ANGPTL1/ABL2) SG and LSI 19p13 (ZNF44/ZNF443/MAN2B1) SG/LSI 19q13 (GLTSCR1/GLTSCR2/CRX) SO dual-color probes from Abbott Molecular, Inc. The probes hybridize to chromosomes 1 and 19, respectively (spectrum green on bands 1q25 and 19p13; and spectrum orange on brands 1p36 and 19q13). The 1p36/1q25 and 19q13/19p13 signal ratio for deletion of 1p36 and 19q13 is 0.80. If the ratio is between 0.8 and 0.95, it is positive for deletion if >50% of cells show deletion. The confidence limit for monosomy 1 or monosomy 19 is 20% of the cells (19) .
RESULTS
Cases
A total of 381 primary brain tumors that previously had been tested by NGS for mutations in cancer-associated genes were included in the study. The cases comprise an array of primary brain tumors, with >90% (351/381, 92.2%) being infiltrating gliomas (ie, astrocytomas or oligodendrogliomas), of which the majority (227/381, 59.5%) were glioblastomas ( Table 1) .
Mutation Analysis in Gliomas
The cases were tested for mutations in cancer-associated genes using commercially available NGS panels. The most commonly mutated genes were TP53 (37.2%), IDH1 (29.4%), PIK3CA (8%), PTEN (8%) and EGFR (7.5%) (Fig. 1) . Interestingly, 32% of cases showed no mutations in any of the regions examined by the NGS assay (Table 1) . No mutations were detected in approximately 37% of glioblastomas (n ¼ 227), 85.7% of ependymomas (n ¼ 7), and 100% of medulloblastomas (n ¼ 6). To investigate how the tumor percentage in the sample submitted for NGS testing affected our ability to detect mutations, we calculated the frequency of TP53 mutations in groups of samples with different tumor percentages. We did not observe an effect on the frequency of detection of TP53 mutations as a result of changes in sample tumor percent (Supplementary Data Fig. 1) .
Genes mutated for each case are listed in Supplementary Data Table 1. Supplementary Data Table 2 summarizes mutations in the diffuse gliomas. The specific amino acid mutations found in the most relevant genes followed the expected relative frequencies that would be predicted based on current literature and databases are presented in Supplementary Data Table 3 . The most common IDH1 and IDH2 mutations were R132H and R172K, respectively. Although PTEN mutations were distributed throughout the entire coding region, R130Q was the most frequent mutation with a frequency of 10%. The most frequent mutations detected in PIK3CA correspond to the known mutation hotspots H1047R, E545K and E542K. The most common TP53 mutation was R273Q with a frequency of 15.2%; although similar to the PTEN gene, mutations were distributed throughout the entire coding region of the gene.
The most commonly mutated genes in glioblastomas were TP53 (35.9%), IDH1 (14.6%), PTEN (10.8%), EGFR (9.2%), and PIK3CA (8.4%) ( Table 2 ). The majority of glioblastomas with an IDH1 mutation also showed a TP53 mutation (28/32, 87.5%). In astrocytomas (WHO grade II/III), the incidence of IDH1 mutations and TP53 mutations was significantly higher, at 63.8% and 59.0%, respectively. The majority of astrocytomas (WHO grade II/III) with an IDH1 mutation also showed a TP53 mutation (45/53, 84.9%). PTEN mutations were more common in glioblastomas (11%) than in lower-grade astrocytomas II/III (3.6%). Nine cases diagnosed as the gliosarcoma variant of glioblastoma were included in the study. All 9 cases were confirmed to be IDH1/IDH2-wildtye; 4 cases were not tested for mutations in IDH2. Five of the 9 (5/9, 55.5%) gliosarcomas showed mutations in the TP53 gene and 2 cases showed mutations in the BRAF gene.
The most common mutations detected in oligodendrogliomas (WHO grade II) were IDH1 (81.8%), PIK3CA (9%), and NRAS (9%). In anaplastic oligodendrogliomas (WHO grade III), the most common mutations were IDH1 (76.19%), TP53 (23.8%), and PIK3CA (19.0%). In contrast to astrocytomas (in which TP53 mutations were common), none of the oligodendrogliomas (WHO grade II) (0/11) and about 23.8% (5/21) of anaplastic oligodendrogliomas showed a TP53 mutation. Also, CDKN2A mutations were observed in 3 anaplastic oligodendrogliomas (WHO grade III) but were not detected in low-grade oligodendrogliomas (WHO grade II), suggesting that CDKN2A, similarly to TP53 mutations, are associated with anaplastic features in oligodendrogliomas. IDH2, CDKN2A, KRAS, and NRAS mutations were more frequent in oligodendrogliomas than astrocytomas (Fig. 2) . Circos plots depicting genetic alterations in glioblastomas and astrocytomas, as well as the relative frequencies of co-existing mutations are shown in Figure 3 .
Gene Amplifications
The number of reads for a particular amplicon is proportional to the number of DNA template molecules in the sample. Thus, depth of coverage obtained from NGS data can be utilized to estimate copy number changes. It is possible to detect gene amplification events by comparing the number of reads for a particular gene in a sample with the average number of reads usually obtained for that gene in all other samples. Eighty-eight (88) of the 381 cases (88/381, 23%) showed evidence of amplification in one the genes included in the NGS panel. The most common genes showing evidence of amplification were EGFR (18.0%), PDGFRA (2.5%) and KIT (1.8%) (Table 3) . Twenty-seven percent (27%) of glioblastomas showed evidence of EGFR amplification, whereas <1% of glioblastomas showed evidence for PDGFRA amplification, consistent with prior reports (9, 20) . In contrast, only 4.6% and 0% of astrocytomas (WHO grades II/III) showed evidence of EGFR or PDGFRA amplification, respectively. Evidence for gene amplification was not seen in oligodendrogliomas (WHO grade II). Two anaplastic oligodendrogliomas (WHO grade III) (2/21, 9.5%) showed evidence of gene amplification (one case for EGFR and the other case for FGFR3). A summary of gene amplifications in diffuse gliomas is shown in Table 4 . 
Correlation of Mutation Analysis With IHC
IHC analysis is an essential part of the diagnostic work up of neoplastic lesions. The incorporation of mutation analysis by DNA sequencing into routine pathology practice creates the need to reconcile sequencing results with the results of IHC tests. We correlated the IHC results with the mutations detected by NGS for routine markers traditionally evaluated by IHC. Sixty-six cases (72.5%) showed some degree of P53 positivity by IHC and 48% showed a mutation in TP53 by NGS ( Table 5 ). The percentage of cases that showed a TP53 mutation by NGS correlated with the IHC results, with cases demonstrating P53 accumulation by IHC showing the highest frequency of TP53 mutations (Table 5) . It is important to realize that a positive result for P53 expression by IHC does not imply the presence of a TP53 mutation because several mechanisms can lead to P53 protein accumulation in the absence of a mutation in the TP53 gene. In our study, out of the 66 cases with some degree of P53 expression by IHC, 37.8% showed no mutations in the TP53 gene by NGS.
EGFR EGFR expression was evaluated by IHC in 82 cases. Fifty-six (56/82, 68.2%) cases were negative for expression of EGFR. Of the 82 cases evaluated for expression of EGFR by IHC, 20 cases showed a positive result, of which 4 (20%) cases showed a mutation in the EGFR gene, whereas only 1 (1.8%) case of the 56 cases that were negative for EGFR expression by IHC showed an EGFR mutation. Although cases that showed expression for EGFR by IHC are more likely to show mutations in the EGFR gene than cases that are negative for EGFR expression, the correlation is not particularly strong (Table 6 ). In contrast, 15/20 (75%) cases with a positive result for EGFR expression by IHC showed indications of EGFR gene amplification as determined by depth of coverage analysis from NGS data ( Table 7) . Of the 56 cases negative for EGFR expression by IHC, only 2 (3.5%) cases showed evidence of EGFR amplification by NGS. These data suggest that a negative result for EGFR expression by IHC is a strong predictor for the absence of EGFR amplification. Whereas a positive result for EGFR expression by IHC is a good predictor of EGFR amplification, the correlation in our study is not strong enough to favor the use of IHC as a surrogate marker for EGFR amplification in the clinical setting. Of the 20 glioblastomas (WHO grade IV) that showed an EGFR mutation, 14/20 (70%) also showed evidence of EGFR amplification, consistent with prior reports of EGFR mutations and amplifications occurring in combination (11).
PTEN
Eighty-two cases were evaluated for expression of PTEN by IHC, of which 13 cases (15.9%) demonstrate partial or complete loss of expression. However, of the 13 cases with some degree of loss of PTEN expression, only 2 (15%) cases demonstrated the presence of a PTEN mutation by NGS. Of the 69 cases that showed retained expression of PTEN by IHC, 6 cases (8.7%) showed a mutation in the PTEN gene by NGS (Table 8) . These data show a poor correlation between PTEN expression by IHC and the presence of a mutation in the PTEN gene. This finding is consistent with the notion that other genetic alterations besides point mutations (ie, copy number changes) play an important role in mediating loss of expression of the PTEN protein (9, 20) .
IDH1
One hundred and sixty-one cases were evaluated for expression of the IDH1-R132H mutant protein by IHC, of which 60 (39.8%) were positive and 97 (60.2%) were negative ( Table 9 ). Out of the 60 cases that demonstrated expression of the IDH1 p.R132H mutant protein by IHC, 60 (100%) cases showed the presence of an IDH1 p.R132H mutation by DNA sequencing analysis thereby demonstrating high sensitivity of the IDH1 p.R132H antibody. Ninety-seven cases were negative for expression of the mutant IDH1 p.R132H protein, of which 12 (12.4%) cases showed an IDH1 mutation and 3 (3.1%) cases showed an IDH2 mutation by sequencing Fisher exact test yielded a p value of 0.6065, indicating that there is no significant association between the 2 variables (IHC and NGS). It is important to keep in mind that copy number changes are a frequent mechanism for loss of PTEN expression that is not detected by the NGS assay used in this study.
analysis. Overall, 15.4% of cases negative for IDH1 p.R132H mutation by IHC demonstrated an IDH1 or IDH2 mutation by sequencing, emphasizing the value of reflex sequencing for IDH1/IDH2 mutations in cases that are negative by an initial IHC assay. The IDH1 mutation found by NGS in the cases that were negative for the IDH1 p.R132H by IHC were noncanonical IDH1 mutations (R132C ¼ 4, R132G ¼ 4, R132S ¼ 2 and P127C ¼ 1), confirming the high specificity of the IDH1 p.R132H antibody. The IDH1 p.P127C mutation has not been reported in COSMIC or ExAC databases (last accessed July 21, 2016) and the functional consequence for IDH1 function is unknown. The frequencies of IDH1 and IDH2 mutations detected by the NGS assay were 44.7% and 2.5%, respectively.
WHO Classification
It is expected that with changes in the criteria for classifying CNS tumors, discrepancies will occur upon retrospective analysis of cases. Three cases with a histologic diagnosis of glioblastoma and 1 case with a histologic diagnosis of anaplastic astrocytoma showed 1p/19q co-deletion by FISH studies. Following the 2016 CNS WHO classification, these cases were reclassified as anaplastic oligodendroglioma, IDHmutant, 1p/19q-codeleted, for the purpose of this study.
One oligodendroglioma that was negative for IDH1 mutations (by NGS and IHC), but with confirmed 1p/19q codeletion, was included in the analysis. Given the presence of the oligodendroglioma morphology and confirmation of 1p/ 19q co-deletion by FISH studies, it will be expected that the tumor has a mutation in the IDH2 gene. Although under the revised WHO 2016 it will be recommended to confirm the presence of the IDH2 mutation in this case, this was not confirmed for the purposes of this study.
In the case of 1 tumor diagnosed as oligodendroglioma, WHO grade II, and 5 cases diagnosed as anaplastic oligodendroglioma, WHO grade III, confirmation of 1p/19q status was not available. The tumors showed IDH1 p.R132H mutation by IHC and sequencing. Under the 2016 CNS WHO classification, these tumors should be classified as oligodendroglioma, NOS (or oligodendroglioma, IDH-mutant, NOS), to communicate the absence of critical molecular information. One case of anaplastic oligodendroglioma showed an IDH1 p.R132H and IDH2 p.P158S mutations. In the setting of an IDH1 p.R132H mutation, the significance of the IDH2 mutation is not known. In addition, it is important to note that the IDH2 p.P158S mutation has not been reported in COSMIC or ExAC databases (last accessed on July 21, 2016), and its effect on IDH2 function remains to be determined.
Diffuse Glioma or Oligoastrocytoma
Twenty-three cases had a diagnosis of diffuse glioma or oligoastrocytoma. Nineteen of the 23 cases were IDH1 mutant, and 4 cases were negative for IDH1/IDH2 mutations. Fifteen (15/23) of the cases were tested for 1p/19q co-deletion with 5 positive and 10 negative cases. Following the 2016 CNS WHO guidelines, integrating the molecular signature information, the 15 cases with available 1p/19q codeletion results were reclassified as oligodendroglioma, IDH-mutant, 1p/ 19q-codeleted, astrocytoma IDH-mutant, or astrocytoma IDHwild-type, for the purposes of this study. The remaining 8 cases for which 1p/19q analysis was not available were excluded from the analysis.
Other Tumors
A single rosette-forming glioneuronal tumor (RFGNT) was included in the study and showed a PIK3CA p.R88Q mutation. Mutations in PIK3CA and FGFR1 are common in RFGNT (21, 22) . Although rare, the R88Q mutation has been previously reported in several tumor types including CNS tumors (23) . A tumor diagnosed as composite pleomorphic xanthoastrocytoma/ganglioglioma showed a RET p.E762D mutation. This particular mutation is located in the kinase domain of the RET gene and has been reported in 1 case of melanoma in the COSMIC database. Only 1 adamantinomatous craniopharyngioma was included in the study. The tumor showed a CTNNB1 p.D32Y mutation. The majority of CTNNB1 mutations found in cancer occur at codons 32-45, with codon 41 being the most commonly affected. The p.D32Y mutation has been reported in several CNS tumor types including PNET and craniopharyngiomas. CTNNB1 mutations are a characteristic genetic abnormality of adamantinomatous craniopharyngiomas, in contrast to papillary craniopharyngiomas that are associated with BRAF p.V600E mutations (24) .
Primary Brain Tumors With the BRAF V600E Mutation
In total, 3% of the 381 primary brain tumors showed the BRAF p.V600E mutation (Table 10 ). The presence of the BRAF p.V600E mutation was not specific for a particular diagnostic entity and was observed in a variety of high grade as well as low-grade tumors. The tumor with the highest frequency of BRAF p.V600E mutation was gangliogliomas (50%), consistent with prior results (25) . Interestingly, 20% of gliosarcomas showed the presence of a BRAF mutation. 
DISCUSSION
We analyzed the results of the NGS panel, IHC and FISH assays in 381 primary brain tumors. Approximately one third of the cases in this study did not show a mutation in any of the genes included in the NGS panel. Our analysis showed that the percentage of tumor in the sample (for samples with 20% tumor or higher) does not limit our ability to detect mutations in TP53. The TP53 gene was selected for the analysis because it is the most frequently mutated gene in our study. It is important to keep this in mind at the time of establishing a diagnosis in cases that the absence of a mutation in an NGS assay should not be used as evidence to support a non-neoplastic process.
Diffuse Glioma
The most common mutations in the 351 infiltrating gliomas were IDH1, TP53, PIK3CA, PTEN, and EGFR, in agreement with prior reports (9) . Among astrocytomas-II/III, 45/53 (85%) cases with an IDH mutation also showed a TP53 mutation and 28/32 (88%) of glioblastomas with an IDH1 mutation also showed a TP53 mutation. The high frequency of infiltrating astrocytomas with a combination of IDH1 and TP53 mutations is also in keeping with prior studies proposing 3 molecular subgroups of diffuse gliomas (IDH-WT, IDH-mutant-1p/19q-codeleted, and IDH-mutant-1p/19q-intact), with IDH-mutant-1p/19q-intact astrocytomas showing a high frequency of TP53 mutations (10) .
None of the astrocytomas-II/III or glioblastomas-IV with an IDH1 mutation showed EGFR mutation or evidence of EGRF amplification. All astrocytomas-II/III and glioblastomas-IV that showed evidence of gene amplification were IDH-wildtype. In particular, 81/204, 39.7% of IDH-wild-type glioblastomas showed evidence of gene amplification. Only 1 IDH-mutant glioblastoma showed a mutation in the PTEN gene, suggesting that IDH1/2 and PTEN mutations rarely co-occur. A subset of glioblastomas (144/233, 61.8%) was not evaluated for IDH2 mutations. However, IDH2 mutations are rare in glioblastomas and are detected in only 1/92 (1%), glioblastomas examined (26) . These data are in agreement with the proposed existence of different genetic pathways for development of primary (IDH-WT) and secondary (IDH-mutant) glioblastomas (27) . IDH mutations are part of the molecular signature of oligodendrogliomas-II/III. Besides IDH1/IDH2, PIK3CA, CDKN2A, and NRAS, there were little additional alterations in oligodendroglial tumors.
Gene amplification events estimated from NGS coverage data were seen in 0% of oligodendrogliomas (WHO grade II), 4.8% of astrocytomas (WHO grade II/III), 9.5% of anaplastic oligodendrogliomas (WHO grade III), and 33% of glioblastomas (WHO grade IV), indicating that copy number changes are more frequent in high-grade gliomas. EGFR and PDGFR amplification events can be detected by the NGS assay and could potentially guide therapeutic intervention. For example, clinical trials evaluating EGFR or PDGFR inhibitors such as erlotinib, lanatinib, nilotinib, or immunotherapy-based approaches directed at EGFR overexpressing tumors are ongoing (NCT01257594, NCT02331693, NCT02101905, and NCT02233049, visit clinicaltrials.gov for a complete list). However, appropriate clinical validation using an alternate testing methodology and calculation of sensitivity and specificity with another method is necessary before utilizing the results of gene amplification for clinical decisions.
Gliosarcoma Variant of Glioblastoma
The 9 cases with a histologic diagnosis of gliosarcoma were negative for mutations in IDH1/IDH2 (4 cases were not analyzed for mutations in IDH2). This finding is in agreement with the 2016 CNS WHO designation of gliosarcoma as an IDH-wild-type entity (2, 28) . TP53 mutations were present in 5/9 gliosarcomas, and BRAF mutations were present in 2/9 gliosarcomas. The 2 cases with a BRAF p.V600E mutation were wild-type for TP53. The occurrence of BRAF mutations have been previously described in 1/16 (6%) of gliosarcomas (25) . It remains to be determined if there are any clinical implications for the small group of patients with glioblastomas that have the BRAF p.V600E mutation.
BRAF Mutations
Although the percent of primary brain tumors with the BRAF p.V600E mutation is not particularly high (3%), clinical trials evaluating BRAF inhibitors for the treatment of BRAF-mutant gliomas are ongoing (NCT01748149, NCT01677741, visit clinicaltrials.gov for a complete list). The potential therapeutic implications of this finding argues for the evaluation of BRAF p.V600E status in brain tumors, in particular in gangliogliomas and gliosarcomas where the frequency of the BRAF V600E alteration was 50% and 22%, respectively. Pilocytic astrocytomas commonly show BRAF alterations (25, 29, 30) , but this tumor type is not well represented in our cohort. Ten glioblastomas (including the 2 gliosarcoma variant) showed a BRAF mutation; in 6/10 cases, the BRAF mutation was the only genetic alteration detected by the NGS panel. The remaining 4 cases showed mutations in FGFR1, PTEN, CDKN2A þ NOTCH1, and EGFR amplification as the additional alterations, respectively. One glioblastoma showed exclusively the presence of a BRAF p.I463M mutation; this particular mutation has not been reported in COSMIC or ExAC databases (last visited on July 21, 2016), and its effect on protein function is unknown.
Molecular Diagnosis
Twenty-three samples had the diagnosis of diffuse glioma or oliogoastrocytoma based on microscopic analysis of H&E-stained sections combined with clinical history, imaging, and ancillary studies. Incorporating the guidelines It is also possible that a small percent of diffuse gliomas with 1p/19q co-deletion but no IDH mutations exist and it remains to be determined how they compare to the molecularly defined counterpart. Interestingly, 1 of the 2 cases showed a KRAS mutation, which is more common in oligodendrogliomas (31) . The practicing neuropathologist is bound to encounter apparent discrepancies in the results of IHC, NGS and FISH studies and additional information such as imaging characteristics, age of the patient, and careful histologic examination might help in reconciling unusual molecular and IHC results.
Clinical Utility
From a practical perspective, the most clinically relevant genes for brain tumors included in the commercial NGS panel utilized in this study are IDH1, IDH2, TP53, PIK3CA, BRAF, EGFR, PDGFRA, and FGFR1, 2 and 3. IDH1 and IDH2 are critical for the diagnosis of diffuse gliomas under the 2016 CNS WHO guidelines, whereas TP53 can be helpful in identifying diffuse gliomas that are 1p/19q-intact because TP53 mutations are rare in tumors with 1p/19q codeletion. Studies from The Cancer Genome Atlas on glioblastomas and lower-grade gliomas have classified diffuse gliomas on molecular subgroups (9, 10, 13) . The 3 molecular subgroups of lower-grade gliomas include IDH-wild-type (astrocytomas), IDH-mutant-1p/19q-intact (astrocytomas), and IDH-mutant1p/19q-codelted (oligodendrogliomas). The IDH-mutant-1p/ 19q-intact group has a high frequency of TP53 and ATRX mutations. The commercial NGS assay serves to identify IDHmutant or IDH-wild-type status and TP53-mutant status, ATRX is not included in the commercial assay. The combination of the NGS assay with a separate assay for 1p/19q status is sufficient for the molecular classification of the majority of adult diffuse gliomas according to the 2016 CNS WHO classification. PIK3CA, BRAF, EGFR, PDGFRA, and FGFR1, 2 and 3 could help guide treatment decisions. There are inhibitors (either available or currently in development for PIK3CA (eg, buparlisib, alpelisib), BRAF (eg, vemurafenib), EGFR (eg, erlotinib), PDGFRA (eg, nilotinib), and FGFR (eg, AZD 4547) for which there are ongoing or soon to open clinical trials. These include basket trials (eg, NCI-MATCH, Pediatric-MATCH and TAPUR trial), in which tumors are treated based on genetic alterations rather than the organ of origin.
Limitations
For the purpose of this retrospective analysis, the most significant difference between the versions 1 and 2 of the NGS panel is the inclusion of the IDH2 gene in version 2. The implication for our analysis is that a portion of the cases included in the study (202/381) were not tested for mutations in the IDH2 gene and our calculations could underestimate the fraction of IDH2 mutant cases. Oligodendrogliomas with 1p/19q co-deletion and no IDH1 mutation will be expected to have mutations in IDH2, but we were not able to confirm the presence of an IDH2 mutation in 2 cases with oligodendroglioma morphology and 1p/19q co-deletion because IDH2 was not sequenced. Six medulloblastomas were included in the study, and no mutations were detected in this group. This finding highlights the fact that many genetic alterations relevant to pediatric brain tumors are not included in the commercially available NGS assays, with CTNNB1 and BRAF genes being notable exceptions. Medulloblastoma-WNT-activated, ependymoma-RELA fusion-positive, and diffuse midline glioma H3 K27M mutant are examples of 2016 CNS WHO entities that cannot be diagnosed with the use of the commercial NGS panel utilized in this study.
